Adalimumab

Fully human monoclonal antibody that binds and neutralizes TNF-alpha

Therapeutic range

5–12 ug/mL

Ctrough > 5 ug/mL for IBD

No curated interaction pairs are recorded for Adalimumab. This is not a statement that none exist — check a full interaction reference before combining.

• Injection site reactions
• Upper respiratory infections
• Headache
• Rash

Half-life

14 days

Protein binding

N/A

Metabolised by

Proteolytic degradation

Clearance

0.012 L/h

adult IBD and RA patients

Volume of distribution

5.5 L

Bioavailability

64%

Renally eliminated

0%

Model

1-compartment

Not recorded for Adalimumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.